- Home
- HSII vs AQST Comparison
HSII vs AQST Comparison
Compare HSII & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- AQST
- Stock Information
- Founded
- HSII 1953
- AQST 2004
- Country
- HSII United States
- AQST United States
- Employees
- HSII N/A
- AQST N/A
- Industry
- HSII Diversified Commercial Services
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- AQST Health Care
- Exchange
- HSII Nasdaq
- AQST Nasdaq
- Market Cap
- HSII 1.0B
- AQST 809.3M
- IPO Year
- HSII 1999
- AQST 2018
- Fundamental
- Price
- HSII $58.81
- AQST $5.80
- Analyst Decision
- HSII Buy
- AQST Strong Buy
- Analyst Count
- HSII 2
- AQST 7
- Target Price
- HSII $57.50
- AQST $10.00
- AVG Volume (30 Days)
- HSII 332.9K
- AQST 2.9M
- Earning Date
- HSII 11-03-2025
- AQST 11-05-2025
- Dividend Yield
- HSII 1.02%
- AQST N/A
- EPS Growth
- HSII N/A
- AQST N/A
- EPS
- HSII 1.73
- AQST N/A
- Revenue
- HSII $1,199,854,000.00
- AQST $43,397,000.00
- Revenue This Year
- HSII $11.42
- AQST N/A
- Revenue Next Year
- HSII $1.39
- AQST $51.39
- P/E Ratio
- HSII $34.00
- AQST N/A
- Revenue Growth
- HSII 11.56
- AQST N/A
- 52 Week Low
- HSII $36.87
- AQST $2.12
- 52 Week High
- HSII $58.85
- AQST $7.55
- Technical
- Relative Strength Index (RSI)
- HSII 74.31
- AQST 47.25
- Support Level
- HSII $58.55
- AQST $5.53
- Resistance Level
- HSII $58.91
- AQST $6.17
- Average True Range (ATR)
- HSII 0.10
- AQST 0.43
- MACD
- HSII -0.21
- AQST -0.03
- Stochastic Oscillator
- HSII 75.00
- AQST 38.11
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.